Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- 2.94 --
11/04/2022* 09:00 EST Earnings Call Q3 2022 -- -- --
07/28/2022 08:00 EST Earnings Call Q2 2022 -- -- --
07/27/2022 -- Results Q2 2022 2.86 2.79 2.42%
04/28/2022 08:00 EST Earnings Call Q1 2022 -- -- --
04/27/2022 -- Results Q1 2022 2.76 2.69 2.52%
02/22/2022 -- Results Q4 2021 2.63 2.65 -0.76%
02/22/2022 09:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/27/2022
Beat/Miss Upgrade
Return Since -17.67%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
URL https://www.iconplc.com
Investor Relations URL https://investor.iconplc.com/
HQ State/Province N/A
Sector Healthcare
Industry Diagnostics & Research
Equity Style Large Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
52.38%
-3.22%
49.14%
15.21%
33.29%
13.21%
58.84%
-38.38%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
92.92%
62.96%
30.19%
239.4%
57.53%
-77.19%
-31.08%
-67.66%
-14.15%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
0.21%
228.1%
-27.78%
-23.79%
-72.53%
53.69%
-24.13%
311.3%
-37.77%
--
-37.40%
0.34%
-75.59%
-9.59%
-81.67%
-75.25%
-84.91%
As of September 23, 2022.

Profile

Edit
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
URL https://www.iconplc.com
Investor Relations URL https://investor.iconplc.com/
HQ State/Province N/A
Sector Healthcare
Industry Diagnostics & Research
Equity Style Large Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
EIRL 1.835M USD 4.08%
BBH 14.74M USD 3.57%
TMFG 13.39M USD 3.31%
WCMRX 638.09M USD 3.16%
SSPX 567558.0 USD 3.00%
JOHAX 229.22M USD 2.74%
JIGIX 204.92M USD 2.22%
MIGBX 198.63M USD 2.06%
OTCGX 277.34M USD 1.97%
QQQN 1.682M USD 1.80%
JVMCX 288.45M USD 1.46%
QQQJ 10.18M USD 1.40%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ICLR Tweets